Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Genetic Variants of Nucleotide Excision Repair Pathway and Outcomes of Induction Therapy in Acute Myeloid Leukemia Publisher Pubmed



Sharifi Z1 ; Faranoush M2 ; Mohseni A3 ; Rostami S4 ; Ramzi M5 ; Sharifi MJ1, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
  2. 2. Rasool Akram Complex Medical Center, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Thalassemia Research Center, Hemoglobinopthy Institute, Mazandaran University of Medical Sciences, Sari, Iran
  4. 4. Haematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
  6. 6. Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

Source: Personalized Medicine Published:2019


Abstract

Aim: Acute myeloid leukemia (AML) is a heterogeneous disease in pathogenesis and response to therapy. Nucleotide excision repair (NER) pathway has a major role in the elimination of genotoxic effects of chemotherapeutic agents. We aimed to clarify the effects of selected variants of XPD, XPC, ERCC5 and ERCC1 genes on the outcomes of induction therapy. Materials & methods: The prevalence of NER genetic variants was evaluated in 67 subjects with AML and their effects on clinical outcomes were analyzed by χ2 test. Results: The XPD 751 Lys variant was associated with improved response to chemotherapy compared with XPD 751 Gln and Lys/Gln variants (p = 0.023; odds ratio: 4.5; 95% CI: 1.14-17.73). There were no associations between other genotypes and any outcomes. Conclusion: Current findings suggest that XPD Lys751Gln variant could be considered as a prognostic factor in AML. © 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Arms-Pcr Versus As-Pcr to Evaluate Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, Tehran University Medical Journal (2010)
2. Evaluation of Rs62527607 [Gt] Single Nucleotide Polymorphism Located in Baalc Gene in Children With Acute Leukemia Using Mismatch Pcr-Rflp, Cancer Genetics (2016)
3. Rad51 135G>C Polymorphism and Risk of Sporadic Colorectal Cancer in Iranian Population, Journal of Cancer Research and Therapeutics (2018)
4. Differential Expression and Pathological Implications of Linc01089 and Linc01578 in Acute Myeloid Leukemia, Gene Reports (2025)
5. Effectiveness of Filgrastim and Polyethylene Glycol-Filgrastim in the Treatment of Postchemotherapy Neutropenia in Children: Phase I Clinical Trial, Indian Journal of Medical and Paediatric Oncology (2019)
6. Single Cell Rna Sequencing Improves the Next Generation of Approaches to Aml Treatment: Challenges and Perspectives, Molecular Medicine (2025)
7. Effects of Abcg2 C421a and Abcg2 G34a Genetic Polymorphisms on Clinical Outcome and Response to Imatinib Mesylate, in Iranian Chronic Myeloid Leukemia Patients, Egyptian Journal of Medical Human Genetics (2023)
8. Cd Markers Polymorphisms As Prognostic Biomarkers in Hematological Malignancies, Oncology Reviews (2020)
Experts (# of related papers)
View all Related Experts
Mohammadreza Sharifi (4)
Valiollah Mehrzad (3)
Other Related Docs
9. Transcription Analysis of a Histones Modifiers Panel Coupled With Critical Tumor Suppressor Genes Displayed Frequent Changes in Patients With Aml.: Mrna Levels of Histones Modifiers and Tsgs in Aml, Current Research in Translational Medicine (2021)
10. The Importance of Personalized Medicine in Chronic Myeloid Leukemia Management: A Narrative Review, Egyptian Journal of Medical Human Genetics (2023)
11. Birc5 Gene Disruption Via Crispr/Cas9n Platform Suppress Acute Myelocytic Leukemia Progression, Iranian Biomedical Journal (2019)
12. Evaluation of Jak2 V617f Mutation and Correlations of This Mutation With Clinical and Laboratory Findings in Patients With Myeloproliferative Neoplasms, Journal of Isfahan Medical School (2010)
13. Immunophenotypic Aberrancy in Acute Leukemia – a Retrospective Single Institute Study, Polish Annals of Medicine (2021)
14. Incidence and Clinical Importance of Bcr-Abl1 Mutations in Iranian Patients With Chronic Myeloid Leukemia on Imatinib, Journal of Human Genetics (2015)
15. Investigating the P53 Codon 72 Polymorphism in Patients With Chronic Myeloid Leukemia in Isfahan, Iran, Journal of Isfahan Medical School (2015)
16. Comparisions of Arms-Pcr and As-Pcr for the Evaluation of Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, International Journal of Hematology-Oncology and Stem Cell Research (2010)
17. Association Between (Gt)N Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients With Acute Leukemia: A Controlled, Cross-Sectional Study, International Journal of Hematology-Oncology and Stem Cell Research (2018)
18. The Correlation Between Pax5 Deletion and Patients Survival in Iranian Children With Precursor B-Cell Acute Lymphocytic Leukemia, Cellular and Molecular Biology (2017)
19. Antiproliferative Effect of Upregulation of Hsa-Let-7C-5P in Human Acute Erythroleukemia Cells, Cytotechnology (2018)
20. Lack of Association Between C1236t, G2677t/A and C3435t Variants of the Abcb1 Gene and Imatinib Response in Iranian Chronic Myeloid Leukemia Patients, Journal of Sciences, Islamic Republic of Iran (2021)